4 research outputs found

    Continuing Response to Subsequent Treatment Lines With Tyrosine Kinase Inhibitors in an Adolescent With Metastatic Renal Cell Carcinoma

    No full text
    A 14-year-old girl with metastatic renal cell carcinoma was treated with nephrectomy, interferon, and several lines of the targeted agents sorafenib, bevacizumab, sunitinib, and everolimus, either alone or in combination. Treatment was well tolerated, but the patient developed hypothyroidism and significant hypertension with bevacizumab and sunitinib. She responded to all agents and was given radiation treatment twice at the time of symptomatic disease progression; she died 33 months from diagnosis
    corecore